
WHAT IS CLAIMED IS:

1. A compound of formula I:



(I)

wherein each of substituents R_1, R_2, R_3 and R_4 is independenently for each instance, selected from the group consisting of hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, and trifluoromethoxy such that exactly two of the subtituents are hydrogen;
X is chosen from the group consisting of a bond, CH_2 and O;
Y is chosen from the group consisting of CH_3 and CF_3;
provided that when R_1 is F, R_2 and R_3 are H, R_4 is trifluoromethoxy, and X is O, Y cannot be CH_3;
or a prodrug, pharmaceutically acceptable salt, or solvate thereof.

2. The compound according to claim 1, wherein:
X is O and Y is CH_3;
X is CH_2 and Y is CH_3;
X is a bond and Y is CH_3; or
X is O and Y is CF_3.

3. The compound according to claim 1, wherein:
R_1 is CH_3, R_2 is H, R_3 is Cl and R_4 is H;
R_1 is CH_3, R_2 is F, R_3 is H and R_4 is H;
R_1 is CH_3, R_2 is H, R_3 is F and R_4 is H;
R_1 is CH_3, R_2 is H, R_3 is H and R_4 is F;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is F;
R_1 is CH_3, R_2 is H, R_3 is H and R_4 is Cl;

R_1 is F, R_2 is H, R_3 is H and R_4 is OCF_3;
R_1 and R_4 are Cl, and R_2 and R_3 are H;
R_1 is Cl, R_2 is H, R_3 is H and R_4 is F;
R_1 is Cl, R_2 is H, R_3 is H and R_4 is OCF_3;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is Cl;
R_1 is F, R_2 is H, and R_3 is H and R_4 is CF_3;
R_1 is OCH_3, R_2 is H, R_3 is H and R_4 is CF_3;
R_1 is F, R_2 is H, R_3 is H and R_4 is CH_3;
R_1 and R_3 are H, and R_2 and R_4 are Cl;
R_1 and R_4 are F, and R_2 and R_3 are H
R_1 and R_3 are H, and R_2 and R_4 are F;
R_1 and R_2 are H, and R_3 and R_4 are F; or
R_1 and R_4 are H, and R_2 and R_3 are OCH_3.

4. The compound according to claim 2, wherein:
R_1 is CH_3, R_2 is H, R_3 is Cl and R_4 is H;
R_1 is CH_3, R_2 is F, R_3 is H and R_4 is H;
R_1 is CH_3, R_2 is H, R_3 is F and R_4 is H;
R_1 is CH_3, R_2 is H, R_3 is H and R_4 is F;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is F;
R_1 is CH_3, R_2 is H, R_3 is H and R_4 is Cl;
R_1 is F, R_2 is H, R_3 is H and R_4 is OCF_3;
R_1 and R_4 are Cl, and R_2 and R_3 are H;
R_1 is Cl, R_2 is H, R_3 is H and R_4 is F;
R_1 is Cl, R_2 is H, R_3 is H and R_4 is OCF_3;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is Cl;
R_1 is F, R_2 is H, and R_3 is H and R_4 is CF_3;
R_1 is OCH_3, R_2 is H, R_3 is H and R_4 is CF_3;
R_1 is F, R_2 is H, R_3 is H and R_4 is CH_3;
R_1 and R_3 are H, and R_2 and R_4 are Cl;
R_1 and R_4 are F, and R_2 and R_3 are H
R_1 and R_3 are H, and R_2 and R_4 are F;
R_1 and R_2 are H, and R_3 and R_4 are F; or

R_1 and R_4 are H, and R_2 and R_3 are OCH_3.

5. The compound according to claim 1 which is selected from the group consisting of:

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[5-chloro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[6-fluoro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[5-fluoro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-4-fluoro-phenyl)-piperidin-1-yl]-[5-fluoro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-fluoro-1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-chloro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1-butyl-7-fluoro-4-trifluoromethoxy-1H-indol-3-yl)-methanone; hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,7-dichloro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-chloro-4-fluoro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-chloro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1-propyl-7-fluoro-4-trifluoromethoxy-1H-indol-3-yl)-methanone; hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-chloro-1-(2-methoxy-ethyl)-7-trifluoromethoxy-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-methyl-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,6-dichloro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,7-difluoro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,6-difluoro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,5-difluoro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[5,6-dimethoxy-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-4-trifluoromethoxy-1-(2-trifluoromethoxy-ethyl)-1H-indol-3-yl]-methanone; and
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-fluoro-7-methyl-1-(2-trifluoromethoxy-ethyl)-1H-indol-3-yl]-methanone.

6. A method for treating a patient suffering from, or subject to, a physiological condition in need of amelioration by inhibition of tryptase, comprising: administering to the patient a therapeutically effective amount of the compound according to Claim 1.

7. The method of Claim 6, wherein the physiological condition is selected from the group consisting of inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung disease, fibrosis, chronic obstructive pulmonary disease, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibroma, hypertrophic scar, dermatological condition, condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcer, and syncytial viral infection.

8. The method of Claim 6, wherein the physiological condition is inflammatory disease.

9. The method of Claim 8 wherein the inflammatory disease is joint inflammation, inflammatory bowel disease, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, asthma or osteoarthritis.

10. The method of Claim 8 wherein the inflammatory disease is inflammatory bowel disease.

11. The method of Claim 6, wherein the physiological condition is COPD.

12. The method of Claim 6, wherein the physiological condition is asthma.

13. The method of Claim 6, wherein the physiological condition is a dermatological condition.

14. The method of Claim 13, wherein the dermatological condition is selected from atopic dermatitis, psoriasis and eczema.

15. A method for treating a patient suffering from asthma, comprising administering to the patient a combination of a therapeutically effective amount of a compound of Claim 1, and a second compound selected from the group consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, a leukotriene receptor antagonist, lipoxygenase inhibitor, a phosphodiesterase-4 inhibitor, and an anti-inflammatory agent.

16. The method of Claim 15, wherein the administering is such that the compound of Claim 1 is preferentially distributed to lung tissue versus plasma.

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.


18. The pharmaceutical composition of Claim 17 further comprising a therapeutically effective amount of a second compound selected from the group

consisting of a beta adrenergic agonist, an anticholinergic, an anti-inflammatory corticosteroid, a leukotriene receptor antagonist, lipoxygenase inhibitor, a phosphodiesterase-4 inhibitor, and an anti-inflammatory agent.

5

WHAT IS CLAIMED IS:

1. A compound of formula I:



(I)

wherein each of substituents R_1, R_2, R_3 and R_4 is independenently for each instance, selected from the group consisting of hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, and trifluoromethoxy such that exactly two of the subtituents are hydrogen;

X is chosen from the group consisting of a bond, CH_2 and O;

Y is chosen from the group consisting of CH_3 and CF_3;

provided that when R_1 is F, R_2 and R_3 are H, R_4 is trifluoromethoxy, and X is O, Y cannot be CH_3;

or a pharmaceutically acceptable salt, or solvate thereof.

2. The compound according to claim 1, wherein:

X is O and Y is CH_3;

X is CH_2 and Y is CH_3;

X is a bond and Y is CH_3; or

X is O and Y is CF_3.

3. The compound according to claim 1, wherein:

R_1 is CH_3, R_2 is H, R_3 is Cl and R_4 is H;

R_1 is CH_3, R_2 is F, R_3 is H and R_4 is H;

R_1 is CH_3, R_2 is H, R_3 is F and R_4 is H;

R_1 is CH_3, R_2 is H, R_3 is H and R_4 is F;

R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is F;

R_1 is CH_3, R_2 is H, R_3 is H and R_4 is Cl;

R_1 is F, R_2 is H, R_3 is H and R_4 is OCF_3;

R_1 and R_4 are Cl, and R_2 and R_3 are H;

R_1 is Cl, R_2 is H, R_3 is H and R_4 is F;

R_1 is Cl, R_2 is H, R_3 is H and R_4 is OCF_3;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is Cl;
R_1 is F, R_2 is H, and R_3 is H and R_4 is CF_3;
R_1 is OCH_3, R_2 is H, R_3 is H and R_4 is CF_3;
R_1 is F, R_2 is H, R_3 is H and R_4 is CH_3;
R_1 and R_3 are H, and R_2 and R_4 are Cl;
R_1 and R_4 are F, and R_2 and R_3 are H
R_1 and R_3 are H, and R_2 and R_4 are F;
R_1 and R_2 are H, and R_3 and R_4 are F; or
R_1 and R_4 are H, and R_2 and R_3 are OCH_3.

4. The compound according to claim 2, wherein:

R_1 is CH_3, R_2 is H, R_3 is Cl and R_4 is H;
R_1 is CH_3, R_2 is F, R_3 is H and R_4 is H;
R_1 is CH_3, R_2 is H, R_3 is F and R_4 is H;
R_1 is CH_3, R_2 is H, R_3 is H and R_4 is F;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is F;
R_1 is CH_3, R_2 is H, R_3 is H and R_4 is Cl;
R_1 is F, R_2 is H, R_3 is H and R_4 is OCF_3,
R_1 and R_4 are Cl, and R_2 and R_3 are H;
R_1 is Cl, R_2 is H, R_3 is H and R_4 is F;
R_1 is Cl, R_2 is H, R_3 is H and R_4 is OCF_3;
R_1 is OCF_3, R_2 is H, R_3 is H and R_4 is Cl;
R_1 is F, R_2 is H, and R_3 is H and R_4 is CF_3;
R_1 is OCH_3, R_2 is H, R_3 is H and R_4 is CF_3;
R_1 is F, R_2 is H, R_3 is H and R_4 is CH_3;
R_1 and R_3 are H, and R_2 and R_4 are Cl;
R_1 and R_4 are F, and R_2 and R_3 are H
R_1 and R_3 are H, and R_2 and R_4 are F;
R_1 and R_2 are H, and R_3 and R_4 are F; or
R_1 and R_4 are H, and R_2 and R_3 are OCH_3.

5. The compound according to claim 1 which is selected from the group consisting of:

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[5-chloro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[6-fluoro-1-(2-methoxy-ethyl)-7-methyl-1 H-indol-3-yl]-methanone;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[5-fluoro-1-(2-methoxy-ethyl)-7-methyl-1 H-indol-3-yl]-methanone;
[4-(5-aminomethyl-4-fluoro-phenyl)-piperidin-I -yl]-[5-fluoro-1 -(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-fluoro-1-(2-methoxy-ethyl)-7-trifluoromethoxy-1 H-indol-3-yl]-methanone;
[4-(5-aminomethyi-2-fluoro-phenyl)-piperidin-1-yl]-[4-chloro-1-(2-methoxy-ethyl)-7-methyl-1H-indol-3-yl]-methanone;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1-butyl-7-fluoro-4-trifluoromethoxy-1 H-indol-3-yl)-methanone; hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,7-dichloro-1-(2-methoxy-ethyl)-1 H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-chloro-4-fluoro-1-(2-methoxyethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-chloro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1-propyl-7-fluoro-4-trifluoromethoxy-1H-indol-3-yl)-methanone; hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-chloro-1-(2-methoxy-ethyl)-7-trifluoromethoxy-1 H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-methyl-1 H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,6-dichloro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;

[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,7-difluoro-1-(2-methoxy-ethyl)-1 H-indol-3-yl]-methanone;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,6-difluoro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4,5-difluoro-1-(2-methoxy-ethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[5,6-dimethoxy-1-(2-methoxyethyl)-1H-indol-3-yl]-methanone hydrochloride;
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-4-trifluoromethoxy-1-(2-trifluoromethoxy-ethyl)-1H-indol-3-yl]-methanone; and
[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[4-fluoro-7-methyl-1-(2-trifluoromethoxy-ethyl)-1H-indol-3-yl]-methanone.

6. A compound according to Claim 1 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the physiological condition is selected from the group consisting of inflammatory disease, a disease of joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung disease, fibrosis, chronic obstructive pulmonary disease, sceleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibroma, hypertrophic scar, dermatological condition, condition related to atherosclerotic plaque rupture, periodontal disease, diabetic retinopathy, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcer, and syncytial viral infection.

7. A compound according to Claim 6 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the physiological condition is inflammatory disease.

8. A compound according to Claim 7 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the inflammatory disease is joint inflammation, inflammatory bowel disease, arthritis, rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, asthma or osteoarthritis.

9. A compound according to Claim 7 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the inflammatory disease is inflammatory bowel disease.

10. A compound according to Claim 6 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the physiological condition is COPD.

11. A compound according to Claim 6 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the physiological condition is asthma.

12. A compound according to Claim 6 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the physiological condition is a dermatological condition.

13. A compound according to Claim 12 for use in treatment of a physiological condition in need of amelioration by inhibition of tryptase, wherein the dermatological condition is selected from atopic dermatitis, psoriasis and eczema.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier thereof.